Tyra Biosciences, Inc. (TYRA)
28.65
+3.79
(+15.25%)
USD |
NASDAQ |
Sep 04, 16:00
28.70
+0.05
(+0.17%)
After-Hours: 20:00
Tyra Biosciences Net Income (Quarterly) : -45.56M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -45.56M |
| March 31, 2026 | -39.30M |
| December 31, 2025 | -33.83M |
| September 30, 2025 | -29.87M |
| June 30, 2025 | -28.10M |
| March 31, 2025 | -28.15M |
| December 31, 2024 | -25.57M |
| September 30, 2024 | -24.02M |
| June 30, 2024 | -18.70M |
| March 31, 2024 | -18.19M |
| December 31, 2023 | -22.83M |
| September 30, 2023 | -21.15M |
| June 30, 2023 | -13.27M |
| Date | Value |
|---|---|
| March 31, 2023 | -11.88M |
| December 31, 2022 | -12.90M |
| September 30, 2022 | -12.51M |
| June 30, 2022 | -15.10M |
| March 31, 2022 | -14.83M |
| December 31, 2021 | -9.93M |
| September 30, 2021 | -6.643M |
| June 30, 2021 | -5.512M |
| March 31, 2021 | -4.209M |
| December 31, 2020 | -3.685M |
| September 30, 2020 | -2.339M |
| June 30, 2020 | -1.838M |
| March 31, 2020 | -1.474M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| CG Oncology, Inc. | -79.06M |
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 45.56M |
| EPS Diluted (Quarterly) | -0.6904 |
| Enterprise Value | 1.361B |
| Earnings Yield | -8.35% |
| Normalized Earnings Yield | -8.352 |